The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
The state-of-the-art facility is expected to be commissioned over the next three years
The move strengthens GBL’s clinical-stage presence in the United States
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Subscribe To Our Newsletter & Stay Updated
